Clinical Efficacy and Safety of a Subcutaneous Immunotherapy With gpASIT+™ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis

Condition:   Hay Fever
Interventions:   Biological: Placebo solution;   Biological: gpASIT+TM
Sponsor:   BioTech Tools S.A.
Not yet recruiting – verified September 2015

View full post on ClinicalTrials.gov: asthma | received in the last 14 days